Table of Contents
DEPRESSION
- EXECUTIVE SUMMARY
- THE FACTS
- What is depression and why are we interested in it?
- PATIENT STATISTICS
- Incidence, diagnosis rates and treatment; now and in the future
- PATIENT MODEL
- Summary of patient population forecasts in seven major markets
(2005A-2012E)
- Model assumptions
- DRUG GROWTH DRIVERS
- DRUG GROWTH RISKS/DAMPENERS
- GLOBAL ANTIDEPRESSANT MARKET
- Global CNS Market (US$68.7 billion)
- GLOBAL SALES SPLIT
- Global sales by region (2005A)
- US market
- Antidepressant US drugs sales by (2005A)
- European market
- European Antidepressant sales by (2005A)
- ROW/Japanese market
- The Major Players Products in 2005 & 2006
- Market share of Antidepressant players by sales (Dec 2005A)
- The Major Players and Products in 2012
- Market share of Antidepressant Players by sales (Dec 2012E)
- CURRENT TREATMENTS
- Leading Brands
- Comparison of leading antidepressant drugs
- Patent Exposure of Current Products
- Patent Exposure of Leading Antidepressant Brands
- ANALYSIS OF LEADING BRANDS
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Lexapro/Cipralex (Forest/Lundbeck)
- Prozac (Eli Lilly)
- Zoloft (Pfizer)
- Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs)
- Cymbalta (Eli Lilly)
- Effexor (Wyeth)
- Noradrenaline and Dopamine Reuptake Inhibitors (NDRIs)
- Wellbutrin (GlaxoSmithKline)
- GLOBAL SALES FORECASTS OF CURRENT TREATMENTS 2005 - 2012
- Sales Forecasts of Current Leading Antidepressant Drugs
- Model assumptions
- NEW DRUGS IN R&D
- Drugs in Development to Treat Depression and Anxiety Related Disorders
- ANALYSIS OF PHASE III DRUGS
- New Drugs in Phase III Development to Treat Depression and Anxiety
- Phase III drugs
- Other Phase III drugs of interest
|
Related Report
|
View Cart
